Company Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. is headquartered in Mississauga, Canada.
| Country | Canada |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Dr. Arun Swarup Menawat MBA, Ph.D. |
Contact Details
Address: 2400 Skymark Avenue, Unit 6 Mississauga, A6 L4W 5K5 Ontario, Canada | |
| Phone | 647-476-1350 |
| Website | profoundmedical.com |
Stock Details
| Ticker Symbol | PROF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628808 |
| CUSIP Number | 74319B502 |
| ISIN Number | CA74319B5027 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arun Swarup Menawat MBA, Ph.D. | Chairman of the Board and Chief Executive Officer |
| Rashed Dewan | Chief Financial Officer |
| Dr. Mathieu Burtnyk | Chief Operating Officer |
| Hartmut Warnken | Chief Commercial Officer of Outside US |
| Abbey Goodman | Chief Commercial Officer of US |
| Stephen Kilmer | Investor Relations |
| Jacques F. Cornet | Senior Vice President and Product Leader Sonalleve |
| Matthew Sobczyk C.A., CPA | Assistant Corporate Controller |
| Levant Tinaz | Software Developer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Mar 26, 2024 | 144 | Filing |
| Mar 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | 40-F | Filing |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | 6-K | Report of foreign issuer |
| Feb 15, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |